SAFFRON #ESMO26: osi+savo vs platinum-pem post-osimertinib, EGFRm MET OE/amp NSCLC
➡️ mPFS 7.6 vs 5.4 mo, HR 0.55
➡️ mOS 17.8 vs 12.9 mo, HR 0.68
➡️ ORR 51 vs 27%
➡️ G≥3 TRAEs 40 vs 52%; edema 49%
Who gets a MET re-biopsy after osimertinib?

@LungCancerRx @OncoAlert @oncodaily